Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites.


Journal

Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 07 01 2021
revised: 09 02 2021
accepted: 13 02 2021
pubmed: 22 2 2021
medline: 13 5 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

Snakebites in Europe are mostly due to bites from Viperidae species of the genus Vipera. This represents a neglected public health hazard with poorly defined incidence, morbidity and mortality. In Europe, fourteen species of "true vipers" (subfamily Viperinae) are present, eleven of which belong to the genus Vipera. Amongst these, the main medically relevant species due to their greater diffusion across Europe and the highest number of registered snakebites are six, namely: Vipera ammodytes, V. aspis, V. berus, V. latastei, V. seoanei and V. ursinii. Generally speaking, viper venom composition is characterised by many different toxin families, like phospholipases A2, snake venom serine proteases, snake venom metalloproteases, cysteine-rich secretory proteins, C-type lectins, disintegrins, haemorrhagic factors and coagulation inhibitors. A suspected snakebite is often associated with severe pain, erythema, oedema and, subsequently, the onset of an ecchymotic area around one or two visible fang marks. In the field, the affected limb should be immobilised and mildly compressed with a bandage, which can then be removed once the patient is being treated in hospital. The clinician should advise the patient to remain calm to reduce blood circulation and, therefore, decrease the spread of the toxins. In the case of pain, an analgesic therapy can be administered, the affected area can be treated with hydrogen peroxide or clean water. However, anti-inflammatory drugs and disinfection with alcohol or alcoholic substances should be avoided. For each patient, clinical chemistry and ECG are always a pre-requisite as well as the evaluation of the tetanus immunisation status and for which immunisation may be provided if needed. The treatment of any clinical complication, due to the envenomation, does not differ from treatments of emergency nature. Antivenom is recommended when signs of systemic envenomation exist or in case of advanced local or systemic progressive symptoms. Recommendations for future work concludes. The aim of this review is to support clinicians for the clinical management of viper envenomation, through taxonomic keys for main species identification, description of venom composition and mode of action of known toxins and provide a standardised clinical protocol and antivenom administration.

Identifiants

pubmed: 33610611
pii: S0300-483X(21)00047-0
doi: 10.1016/j.tox.2021.152724
pii:
doi:

Substances chimiques

Antivenins 0
Viper Venoms 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

152724

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Matteo R Di Nicola (MR)

Via Bobbio, 20144 Milano, Italy. Electronic address: matteodinicola86@libero.it.

Andrea Pontara (A)

Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.

George E N Kass (GEN)

European Food Safety Authority, Scientific Committee and Emerging Risks unit, 43126 Parma, Italy.

Nynke I Kramer (NI)

Institute for Risk Assessment Sciences, University of Utrecht, Utrecht, the Netherlands.

Ignazio Avella (I)

CIBIO/InBIO - Centro de Investigação em Biodiversidade e Recursos Genéticos da Universidade do Porto, Rua Padre Armando Quintas 7, 4485-661, Vairão, Portugal; Evolutionary and Translational Venomics Laboratory, Instituto de Biomedicina de Valencia - CSIC, Calle Jaime Roig 11, 46010, Valencia, Spain.

Riccardo Pampena (R)

Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy.

Santo Raffaele Mercuri (SR)

Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy.

Jean Lou C M Dorne (JLCM)

European Food Safety Authority, Scientific Committee and Emerging Risks unit, 43126 Parma, Italy.

Giovanni Paolino (G)

Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH